Talquetamab for Advanced Multiple Myeloma Up for Approval in EU
Janssen Pharmaceuticals is seeking European Union approval for talquetamab, a subcutaneous (under-the-skin) antibody therapy for hard-to-treat multiple myeloma. The request, in the…
News
FDA Asked to Approve Talquetamab for Hard-to-treat Multiple Myeloma
Janssen has submitted an application with the U.S. Food and Drug Administration (FDA) asking that talquetamab be approved to treat relapsed or refractory…
International Myeloma Foundation Wins 2022 AWS IMAGINE Grant
The International Myeloma Foundation (IMF) is one of the nonprofit organizations awarded the 2022 Amazon Web Services (AWS) IMAGINE Grant, which was established to…
SP-3164 ‘Molecular Glue’ Stops Growth In Lab-grown Cells, Mice
SP-3164, an investigational small molecule protein degrader, showed potential for improved anti-multiple myeloma activity over similar approved compounds. That’s according to preclinical data from…
Phase 1 Trial to Test ‘Off-the-shelf’ CAR T-cell Therapy CB-011 in 2023
Caribou Biosciences will soon start testing its new CAR T-cell therapy candidate, CB-011, in people with relapsed or refractory multiple myeloma. A Phase…
Dual FasTCAR T-Cell Therapy Effective Against Multiple Myeloma
GC012F, Gracell Biotechnologies’ investigational dual FastCAR T-cell therapy, was safe and highly effective at eradicating cancer cells in people with high-risk, newly diagnosed…
FDA Reviewing Motixafortide, Now Aphexda, for Stem Cell Transplants
The U.S. Food and Drug Administration (FDA) will review BioLineRx’s application to approve Aphexda, formerly known as motixafortide, as an add-on stem cell…
Real-world Study Supports Blenrep for Hard-to-treat RRMM
The efficacy and safety of Blenrep (belantamab mafodotin) as a treatment for relapsed/refractory multiple myeloma (RRMM) in a real-world setting is similar to what…
Tecvayli Approved in US for Heavily Pre-treated RRMM, With Conditions
Janssen’s Tecvayli (teclistamab) has been approved for certain adults with relapsed or refractory multiple myeloma in the U.S., but access is limited due…
1st Patient Dosed in Phase 1/2 Trial of Antibody Therapy ISB 1442
The first patient has been dosed in Ichnos Sciences’ Phase 1/2 clinical trial investigating ISB 1442, an experimental bi-specific antibody treatment for people with…
Recent Posts
- Treatment before surgery slows PDAC disease progression: Study
- Scientists discover tissue differences in brain cancer in children
- Elahere approved in EU as treatment for ovarian cancer
- Survival better with Blenrep combo than Darzalex for R/R myeloma
- Aucatzyl, a cell therapy, approved in US for adults with advanced B-ALL